Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...

Drug compounders sued the U.S. Food and Drug Administration on Monday over its decision last week to remove Novo Nordisk's ...

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity ...

Coverage complications are not unusual in the U.S. health care system. But the challenge is magnified for these obesity ...

The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and ...

While the outcomes can be positive, Consumer Reports warns there are important considerations, especially for older adults, ...

Even a little weight loss can work wonders for your health. A study found that people at high risk for developing type 2 diabetes who lost 5 to 7 percent of their weight had a 58% lower risk of ...

Hims & Hers Health shares plunged in extended trading Monday after the online healthcare provider reported falling margins as costs rose.

The Food and Drug Administration on Friday said the shortage of Novo Nordisk's weight-loss and diabetes drugs Wegovy and Ozempic is resolved, a move that could limit the availability of cheaper ...

The latest weight-loss drugs including Ozempic, Wegovy, Mounjaro, and Zepbound have list prices ranging from $900 to $1,500 for a one-month supply. David Ricks, the CEO of Mounjaro and Zepbound ...

The FDA declared the end of the shortage of Novo Nordisk’s Wegovy and Ozempic, impacting compounding pharmacies selling ...